Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649151 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 4,328
- Enrollment target
NCT04649151 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 4,328 participants.
The verdict
NCT04649151, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4,328 participants
- Enrollment target
Study Summary
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series and a booster dose (BD) to an adolescent population. The study will also evaluate the safety and immunogenicity of an mRNA-1273.222 vaccine against the SARS-CoV- 2 omicron variant as a primary series.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1273
- BIOLOGICAL mRNA-1273.222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,328 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2024-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649151
The ClinicalTrials.gov registry entry for NCT04649151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4,328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04649151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04649151 about?
NCT04649151 is a clinical study titled "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19". The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series...
What is the current status of trial NCT04649151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,328 participants. The study started on 2020-12-09. Estimated completion is 2024-06-14.
What interventions are being tested in trial NCT04649151?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273 (BIOLOGICAL), mRNA-1273.222 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04649151?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.